GPT-Rosalind: AI Drug Discovery Gets a Boost

OpenAI just dropped GPT-Rosalind, a new AI model built specifically for life sciences research. It’s designed to speed up drug discovery and molecular biology work by helping scientists navigate massive amounts of data, literature, and experiments more efficiently. Think of it as a supercharged research assistant that can reason through chemistry, proteins, and genomics, plus use over 50 scientific tools directly—aiming to cut down the typical 10-15 year drug development timeline. The model is available via ChatGPT, Codex, and API for select customers, with big partners like Amgen and Moderna already testing it. Named after Rosalind Franklin, the scientist behind DNA’s structure discovery, this release signals a shift toward purpose-built AI for specialized fields—not just general chatbots. Why it matters: As AI moves from broad tools to domain-specific powerhouses, this could dramatically compress the early stages of drug discovery, where most breakthroughs get stuck.